Immunosuppressive effects of voclosporin in inflammatory bowel disease through targeted inhibition of SLP-76 and metabolic reprogramming. (PubMed, J Immunol) - Jul 26, 2026 - "Although calcineurin inhibitors such as cyclosporine A (CsA) are used in severe ulcerative colitis, voclosporin (VCS), a novel calcineurin inhibitor approved for lupus nephritis, has not been systematically evaluated in IBD. Metabolomic profiling showed that VCS induced distinct metabolic changes compared with CsA. Our findings highlight SLP-76 as a potential immunoregulatory target in IBD and suggest that VCS exerts broader immunosuppressive effects than CsA, supporting its repurposing as a therapeutic strategy."
IO biomarker • Journal • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • Immunology • Inflammation • Inflammatory Arthritis • Inflammatory Bowel Disease • Lupus • Lupus Nephritis • Metabolic Disorders • Nephrology • Ulcerative Colitis • CD4 • CD69 • CD8 • LCP2
|
|
Annkathrin Knauss; Arne Gessner; Benno Weigmann; Laura Loges; Markus F Neurath; Michael Gabel; Nora Bartels; Raja Atreya
|